ASX:VHL OTCQB:VHLUF



29 May 2025

#### **EXPIRY OF LISTED OPTIONS ON 30 JUNE 2025 – VHLO**

Dear Option Holder,

You are the registered holder of the listed options VHLO (Exercise Price of \$0.065 per Option) in Vitasora Health Limited (Options) which are due to expire on 30 June 2025 (Expiry Date).

There are three courses of action available to holders of these soon to expire Options.

#### 1. Exercise the Options

To exercise the Options, please complete the Exercise of Options Notice accompanying this letter and provide the completed Exercise of Options Notice with payment of \$0.065 per Option being exercised according to the instructions on the Exercise of Options Notice.

The completed Exercise of Options Notice and payment of cleared funds must be received by the Company no later than 5.00pm (AEST) on Monday, 30 June 2025.

#### 2. Sell the Options

Official quotation of the Options on ASX will cease at close of trading on Tuesday, 24 June 2025, being four business days before the Expiry Date.

#### 3. Do nothing and allow the Options to expire

The Options will expire at 5.00pm (AEST) on Monday, 30 June 2025 and Option Holders right to subscribe for fully paid Ordinary Shares in the capital of the capital at \$0.065 per Share will lapse and all rights will cease.

In accordance with clause 5.2 of Appendix 6A of the ASX Listing Rules, the following information is provided:

- (a) This notice is being sent to all eligible Option Holders in accordance with clause 5.2 of Appendix 6A of the ASX Listing Rules.
- (b) The number of listed Options on issue at current and the number of fully paid Ordinary Shares to be issued if all the Options are exercised is 76,186,219.
- (c) The exercise price of the Options is \$0.065 per Option.
- (d) The Options must be exercised, and payment of cleared funds must be received by 5.00pm (AEST) on the Expiry Date.
- (e) If holders do not exercise or sell their Options prior to the Expiry Date, the Options will lapse, and all rights will cease.
- (f) Official quotation of the Options will cease at close of trading on Tuesday, 24 June 2025, being four business days before the Expiry Date.

- (g) The market price of the Company's Shares on ASX on 27 May 2025 was \$0.041, being the latest available market price of Shares on ASX prior to the date of this letter.
- (h) During the three months preceding the date of this letter
  - The highest market sale price of Shares on ASX was \$0.05 on 26 February, 3 and 4 March 2025; and
  - The lowest market sale price of Shares on ASX was \$0.027 on 7 April 2025.
- (i) There are no underwriting agreements in relation to the Options.

Should there be any further queries, please do not hesitate to contact the Company Secretary at <a href="mailto:justin@jmcorp.com.au">justin@jmcorp.com.au</a>

#### - ENDS -

#### For further information, investors and media please contact:

Mr Marjan Mikel Mr Nicholas Smedley

CEO & Managing Director

Vitasora Health Limited

P: +61 408 462 873

Chairman

Vitasora Health Limited

P: +61 447 074 160

+01 400 402 6/5 P. +01 447 0/4 10

E: marjan@vitasorahealth.com E: nicholas@vitasorahealth.com

# This ASX announcement has been authorised for release by the Board of Directors of Vitasora Health Limited.

#### About Vitasora Health Limited - A Revolutionary Remote Healthcare Solutions Provider

Vitasora Health Limited (ASX:VHL, OTCQB:VHLUF) is redefining digital Connected Care in the U.S. healthcare market. We combine cutting-edge technologies and expert clinical teams to deliver a turnkey solution for providers. Our remote patient monitoring (RPM) and chronic care management (CCM) services improve outcomes, reduce costs, and help healthcare clients thrive in a value-based world. Partnering with healthcare providers and organisations we empower our clients to extend exceptional care into the community, making a real difference to patients' lives.

We are revolutionising healthcare one patient at a time with our disruptive business model, which provides personalised and responsive care. Our cutting-edge R&D sets us apart, offering comprehensive Connected Care Management programs for all major chronic conditions, including our exclusive remote wheeze detection for respiratory disorders.

Through strategic partnerships, we seamlessly integrate our advanced solutions into existing systems and workflows, boosting efficiency and significantly reducing overall healthcare costs. Our data-driven programs and superior clinical expertise position us at the forefront of chronic disease management, ensuring patients' healthcare needs are met consistently and effectively across the continuum of care.

Learn more at www.vitasorahealth.com.au

#### About the wheezo® Medical Device

wheezo®, a world-first FDA-approved Class II medical device, is the sole WheezeRate detector capable of integrating into RPM programs. Developed by Vitasora, wheezo® utilises innovative technology to analyse breath sounds for wheeze. The device works with the user-friendly respiri™ app, enabling users to log symptoms and triggers. The wheezo® system creates a comprehensive and

individualised patient profile, fostering informed dialogues between patients and physicians. For details on our US offering, visit <a href="https://respiri.co/us/">https://respiri.co/us/</a> or for <a href="https://respiri.co/us/">wheezo®</a>

Vitasora Health Limited is headquartered in Melbourne with offices in Los Angeles.

wheezo® is a registered trademark of Vitasora Health Limited

#### Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Vitasora current expectations, estimates and projections about the industry in which Vitasora operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the control of Vitasora, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Vitasora cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Vitasora only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Vitasora will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.



Vitasora Health Limited ABN 98 009 234 173

## For all enquiries:

Vitasora Health Limited: +61 3 8630 3321

By Email:

Phone:

Justin@jmcorp.com.au

#### SRN/HIN:

For your security keep your SRN/ HIN confidential.

# **Notice of Exercise of Listed Options**

### Listed Options exercisable at \$0.065 per Option expiring at 5:00pm (AEST) on 30 June 2025

Dear Optionholder(s)

You are reminded that the Options to subscribe for Fully Paid Ordinary Shares in the capital of Vitasora Health Limited registered in your name expire at 5:00pm (AEST) on 30 June 2025.

These Options are exercisable wholly or in part by the payment of \$0.065 for each Option exercised. Payment must be received by 5:00pm (AEST) on 30 June 2025. For every one Option exercised, the Optionholder will be allotted one Fully Paid Ordinary Share in the capital of Vitasora Health Limited.

#### **Step 1: Registration Name**

Please check the details provided and update your address via www.investorcentre.com if any of the details are incorrect.

#### **Step 2: Make Your Payment**

By making your payment you confirm that you agree to all of the terms and conditions of Listed Option Expiry Notice.

Payments must be remitted to the company's bank account:

Account Name: Vitasora Health Ltd

BSB: 083-004

Account Number: 86-618-8286

Bank: National Australia Bank

SWIFT Code: NATAAU3303M

Please include your SRN/HIN as the bank reference. When submitting your payment electronically please email your completed Listed Option Expiry Notice to the Company Secretary at <a href="mailto:justin@jmcorp.com.au">justin@jmcorp.com.au</a> or by

post:

JM CORPORATE SERVICES Level 21, 459 Collins Street, Melbourne, Vic 3000

#### By submitting this Notice of Exercise of Listed Option or by making payment by EFT:

- I/We request that you allot me/us the number of Fully Paid Ordinary Shares applied for and I/we agree to accept such shares subject to the Constitution of the Company; and
- I/We authorise you to register me/us as the holder(s) of the Fully Paid Ordinary Shares to be alloted and place my/our name on the register.

Vitasora Health Limited Notice of Exercise of Listed Options Payment must be received by 5:00pm (AEST) on 30 June 2025

Notice of Exercise of Listed Options  STEP 1 Registration Name & Optionholding Details		SRN/HIN:  For your security keep your SRN/ HIN confidential.
Optionholding Details:	Number of Options registered in your name as at 28 May 2025:	
	Number of Shares to be issued on full exercise basis:	
	Amount payable on full exercise at \$0.065 per Option:	\$
STEP 2 Make Yo	our Payment	
By making your payment you	confirm that you agree to all of the terms and conditions of Unlisted Option	Expiry Notice.
Payments must be remitted to	the company's bank account:	
Account Name: Vitasora Heal BSB: 083-004 Account Number: 86-618-828 Bank: National Australia Bank SWIFT Code: NATAAU3303N	6	
	as the bank reference. When submitting your payment electronically pleas Secretary at justin@jmcorp.com.au or by post:	e email your completed Listed Option
JM CORPORATE SERVICES Level 21, 459 Collins Street, Melbourne, Vic 3000		
maintaining registers of security us on their behalf to send you m contacting Computershare using under the Corporations Act 200 other individuals or companies or registers or to third parties upon by law. Some of these recipients Kingdom and the United States	ovide on this form is collected by Computershare, as registrar for the securities in holders, facilitating distribution payments and other corporate actions and communicating material or include such material in a corporate communication. You may the details provided above or emailing privacy@computershare.com.au. We may 1 (Cth) and ASX Settlement Operating Rules. We may disclose your personal in who assist us in supplying our services or who perform functions on our behalf, the direction by the issuer where related to the issuers administration of your secures may be located outside Australia, including in the following countries: Canada, of America. For further details, including how to access and correct your person please contact our Privacy Officer at privacy@computershare.com.au or see our	nunications. In addition, the issuer may authorise ay elect not to receive marketing material by ay be required to collect your personal informatic formation to our related bodies corporate and to o the issuer for whom we maintain securities ityholding, or as otherwise required or authorised India, New Zealand, the Philippines, the United al information, and information on our privacy
	mited - Option and Payment Details	
Number of Options Exercise	d:	

Daytime Telephone -

Payable at \$0.065 per Option exercised:

**Contact Details** 

Contact Name —